Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30780978 | 0.84 | TSHR (0.53) | TSHRLMNAALDH1A1ACHEACP3 | |
| SCHEMBL11208136 | 0.84 | TSHR (0.53) | TSHRLMNAALDH1A1ACHEACP3 | |
| SCHEMBL5243706 | 0.83 | TSHR (0.52) | TSHRLMNAALDH1A1ACHEACP3 | |
| SCHEMBL20681151 | 0.83 | TSHR (0.52) | TSHRLMNAALDH1A1ACHEACP3 | |
| SCHEMBL10415892 | 0.83 | TSHR (0.52) | TSHRLMNAALDH1A1ACHEACP3 | |
| SCHEMBL10638754 | 0.81 | ATM (0.51) | TSHRLMNAALDH1A1ACHEACP3 | |
| SCHEMBL7273906 | 0.80 | ALDH1A1 (0.53) | TSHRLMNAALDH1A1ACHEACP3 | |
| SCHEMBL11215770 | 0.80 | TSHR (0.50) | TSHRLMNAALDH1A1ACHEACP3 | |
| SCHEMBL1025506 | 0.80 | ALDH1A1 (0.43) | TSHRLMNAALDH1A1ACP3MAPT | |
| SCHEMBL254876 | 0.79 | TSHR (0.61) | TSHRLMNAALDH1A1ACHEACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109394766-A | A kind of taxol and to benzene nitrophthalide zionoes BTK inhibitor drug combination compositions and its application | 南京先进生物材料与过程装备研究院有限公司 | 2019-03-01 | — | — | CN | claimed |
| CN-109331018-A | A kind of taxol and nitro phthalazone BTK inhibitor drug combination compositions and its application | 南京先进生物材料与过程装备研究院有限公司 | 2019-02-15 | — | — | CN | claimed |
| CN-109276571-A | A kind of taxol and novel nitro phthalazone BTK inhibitor drug combination compositions and its application | 南京先进生物材料与过程装备研究院有限公司 | 2019-01-29 | — | — | CN | claimed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-109394766-A | A kind of taxol and to benzene nitrophthalide zionoes BTK inhibitor drug combination compositions and its application | 南京先进生物材料与过程装备研究院有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-109331018-A | A kind of taxol and nitro phthalazone BTK inhibitor drug combination compositions and its application | 南京先进生物材料与过程装备研究院有限公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-109276571-A | A kind of taxol and novel nitro phthalazone BTK inhibitor drug combination compositions and its application | 南京先进生物材料与过程装备研究院有限公司 | 2019-01-29 | — | — | CN | disclosed |
| WO-2018029264-A1 | PROCESS FOR PREPARATION OF DAPAGLIFLOZIN AND INTERMEDIATES THEREOF | AMNEAL PHARMACEUTICALS COMPANY GMBH (CH) | 2018-02-15 | — | — | WO | disclosed |
| US-6340670-B1 | THERAPY OF RESTENOSIS RESULTING FROM A VASCULAR ANGIOPLASTY PROCEDURE, VASCULAR RECONSTRUCTIVE SURGERY, OR ORGAN OR TISSUE TRANSPLANTATION, FOR INHIBITING ANGIOGENESIS IN A MALIGNANT TUMOR, SARCOMA, OR NEOPLASTIC TISSUE IN A MAMMAL | AMERICAN HOME PRODUCTS CORPORATION | 2002-01-22 | — | — | US | disclosed |
| CN-1328566-A | Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation | AMERICAN HOME PROD (US) | 2001-12-26 | — | — | CN | disclosed |
| EP-1150689-A1 | CHEMICAL COMPOUNDS | NORSK HYDRO ASA (NO) | 2001-11-07 | — | — | EP | disclosed |
| EP-1133509-A1 | ACETAL BENZYLMALTOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000048609-A1 | CHEMICAL COMPOUNDS | NORSK HYDRO ASA (NO) | 2000-08-24 | — | — | WO | disclosed |
| WO-2000031096-A1 | ACETAL BENZYLMALTOSIDES AS INHIBITORS OF SMOOTH MUSCLE CELL PROLIFERATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-0305812-B1 | PROCESS FOR THE PURIFICATION OF NITROBENZALDEHYDE | BAYER AG (DE) | 1992-03-18 | — | — | EP | disclosed |
| US-4910345-A | Using water, emulsifier mixture without crystallization; separation | BAYER AKTIENGESELLSCHAFT (DE) | 1990-03-20 | — | — | US | disclosed |
| EP-0305812-A2 | Process for the purification of nitrobenzaldehyde | BAYER AG (DE) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | TSHR 4606/4885LMNA 531/4885ALDH1A1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.